--- title: Dexcom (DXCM) — intrinsic value and fair price canonical: https://sweetvaluelab.com/stocks/dxcm ticker: DXCM as_of: 2026-10-17 sector: Healthcare industry: Medical - Devices --- # Dexcom (DXCM) Dexcom (DXCM) closed at $86.04 on Oct 16, 2026, overvalued by 226% vs its model value of $26.38 (from a five-year discounted cash flow). ## Key figures | Figure | Value | | --- | ---: | | Last close | $86.04 (Oct 16, 2026) | | Model value (from a five-year discounted cash flow) | $26.38 | | Price vs model | overvalued by 226% vs model | | Range of that model | $18.23 – $47.40 | | Market value | $32.5B | | P/E (fiscal 2025) | 41.2 | | Net margin (fiscal 2025) | 17.9% | | Free cash flow (fiscal 2025) | $1.1B | | Dividend yield (trailing twelve months) | 0.00% | | Beta | 1.48 | | Cost of capital (WACC) | 10.31% | | Business classification | Profitable Growth (Moderate growth (~13% recent), Moderate margins (18% net margin), Highly cyclical earnings) | ## Valuation models Each model's value per share and the role the engine gave it for this business. The headline above is one model's value; every other model is listed with its own, and each has a page of its own under the valuation. Computed Oct 17, 2026. | Model | Role | Value per share | Low | High | | --- | --- | ---: | ---: | ---: | | DCF · Perpetuity growth · 5y | primary | $26.38 | $18.23 | $47.40 | | DCF · Perpetuity growth · 10y | cross check | $31.81 | $22.16 | $56.43 | | DCF · EBITDA exit · 5y | cross check | $26.84 | $12.78 | $43.51 | | DCF · EBITDA exit · 10y | cross check | $32.18 | $17.95 | $51.59 | | P/E · peers | cross check | $0.00 | $0.00 | $0.00 | | P/E · own history | cross check | $227.53 | $123.53 | $352.15 | | PEG | sanity check | $51.08 | $51.08 | $51.08 | | EV/EBITDA · peers | cross check | $22.13 | $0.00 | $44.47 | | EV/Revenue · peers | cross check | $140.83 | $11.76 | $289.62 | | Earnings power value | cross check | $0.02 | $0.00 | $0.16 | ## Insider activity (SEC Form 4) Past 90 days: 0 open-market buys ($0) and 14 open-market sales ($6.6M); 10b5-1 plan sales included. | Date | Insider | Relationship | Transaction | Shares | Value | | --- | --- | --- | --- | ---: | ---: | | Sep 28, 2026 | Stern Sadie | EVP Chief People & Culture Off | Open-market sell (10b5-1 plan) | 2,565 | $220,974.8 | | Sep 14, 2026 | AUGUSTINOS NICHOLAS | Director | Open-market sell (10b5-1 plan) | 1,550 | $130,231 | | Sep 15, 2026 | AUGUSTINOS NICHOLAS | Director | Open-market sell (10b5-1 plan) | 6,539 | $549,537.6 | | Sep 15, 2026 | Brown Michael Jon | EVP Chief Legal Compliance Off | Open-market sell (10b5-1 plan) | 1,700 | $142,868 | | Sep 10, 2026 | Sylvain Jereme M | EVP, Chief Financal Officer | Open-market sell (10b5-1 plan) | 3,638 | $302,936.3 | ## Recent SEC filings | Filed | Form | What | Filing | | --- | --- | --- | --- | | Sep 14, 2026 | 8-K | 5.02 Departure/Election of Directors or Officers; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits | https://www.sec.gov/Archives/edgar/data/1093557/000109355726000175/dxcm-20260910.htm | | Sep 10, 2026 | 8-K | 5.02 Departure/Election of Directors or Officers; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits | https://www.sec.gov/Archives/edgar/data/1093557/000109355726000167/dxcm-20260910.htm | | Jul 30, 2026 | 10-Q | Quarterly report | https://www.sec.gov/Archives/edgar/data/1093557/000109355726000143/dxcm-20260630.htm | | Jul 30, 2026 | 8-K | 2.02 Results of Operations (Earnings); 9.01 Financial Statements and Exhibits | https://www.sec.gov/Archives/edgar/data/1093557/000109355726000142/dxcm-20260730.htm | | May 28, 2026 | 8-K | 5.07 Submission of Matters to a Shareholder Vote | https://www.sec.gov/Archives/edgar/data/1093557/000109355726000105/dxcm-20260527.htm | ## Superinvestors holding it (latest 13F) | Manager | Quarter | Shares | Value | | --- | --- | ---: | ---: | | Bridgewater | 2026-06-30 | 400,929 | $27.0M | 1 tracked managers in all. ## About DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Irela… --- Source: https://sweetvaluelab.com/stocks/dxcm (SweetValueLab, free, no account). Prices and statements from Financial Modeling Prep; filings from SEC EDGAR. Research and educational data, not investment advice; nothing here is a recommendation to buy, sell or hold any security.